Vera Therapeutics, INC Form 4 insider transactions

Vera Therapeutics' Chief Medical Officer, Robert Brenner, was granted 25,000 restricted stock units and options to purchase 50,000 shares of Class A Common Stock.

Vera Therapeutics' Chief Regulatory Officer, William D. Turner, exercised stock options and subsequently sold a portion of his Class A Common Stock.

Vera Therapeutics Director Patrick G. Enright acquired 5,882 shares of Class A Common Stock for $42.50 per share, signaling confidence in the company.

Vera Therapeutics' Chief Regulatory Officer, William D. Turner, exercised stock options and subsequently sold 10,000 shares of Class A Common Stock under a pre-arranged trading plan.

Vera Therapeutics' Chief Regulatory Officer, William D. Turner, exercised stock options and subsequently sold 10,000 shares of Class A Common Stock.

Vera Therapeutics Director James R Meyers was granted 25,000 stock options with an exercise price of $29.43, vesting over three years.

Vera Therapeutics' Chief Legal Officer, Jason S. Carter, sold 3,864 shares of Class A Common Stock to cover tax withholding obligations.

Vera Therapeutics SVP of Finance and Chief Accounting Officer Joseph R. Young reported the sale of 15,000 Class A Common Stock shares and the exercise of options for 10,000 shares.

Vera Therapeutics, Inc. Director and 10% owner Patrick G. Enright, through affiliated funds, acquired over 250,000 shares of Class A Common Stock in late June 2025, signaling increased insider confidence.

Director Andrew Cheng acquired 14,000 stock options in Vera Therapeutics, Inc. on May 14, 2025, according to a Form 4 filing.

Director Maha Katabi acquired 14,000 stock options in Vera Therapeutics, Inc. on May 14, 2025.

Director Patrick G. Enright reports acquisition of 14,000 stock options in Vera Therapeutics, Inc.

Director Christy J. Oliger acquired 14,000 stock options in Vera Therapeutics, Inc. on May 14, 2025, according to a Form 4 filing.

Michael Morrissey, a director of Vera Therapeutics, acquired 14,000 stock options on May 14, 2025, exercisable at $21.19.

Director Beth C. Seidenberg acquired 14,000 stock options in Vera Therapeutics, Inc. on May 14, 2025.

Director Kimball Hall acquired 14,000 stock options in Vera Therapeutics, Inc. on May 14, 2025, according to a Form 4 filing.

Director Scott W. Morrison acquired 14,000 stock options in Vera Therapeutics, Inc. on May 14, 2025, at an exercise price of $21.19.

Marshall Fordyce, CEO of Vera Therapeutics, reports sales of Class A Common Stock to cover tax withholding obligations related to vesting restricted stock units and sales pursuant to a pre-arranged trading plan.

Joseph R. Young, SVP of Finance and Chief Accounting Officer at Vera Therapeutics, reports acquisition of shares and stock options.

William D. Turner, Chief Development Officer of Vera Therapeutics, acquired shares and stock options in a transaction reported on February 18, 2025.

Robert Brenner, Chief Medical Officer of Vera Therapeutics, reports acquisition of stock options and restricted stock units.

Sean Grant, CFO of Vera Therapeutics, reports the acquisition of stock and option awards, including 26,900 shares of Class A Common Stock underlying restricted stock units and options to purchase 53,800 shares.

Marshall Fordyce, CEO of Vera Therapeutics, reports acquisition of shares and stock options.

David Lee Johnson, Chief Operating Officer of Vera Therapeutics, reports acquisition of shares and stock options.

CEO Marshall Fordyce exercised stock options and sold shares of Vera Therapeutics (VERA) on January 8, 2025, according to a Form 4 filing with the SEC.

Marshall Fordyce, CEO of Vera Therapeutics, exercised stock options and sold shares of Class A Common Stock under a pre-arranged Rule 10b5-1 trading plan.

Vera Therapeutics CEO, Marshall Fordyce, engaged in multiple stock transactions, including both acquisitions and disposals, under a pre-arranged 10b5-1 trading plan.

Vera Therapeutics CEO, Marshall Fordyce, exercised stock options and sold shares on November 25, 2024, under a pre-arranged 10b5-1 trading plan.

Vera Therapeutics' Chief Legal Officer, Jason S. Carter, acquired 53,000 shares of Class A Common Stock and 108,000 stock options on November 18, 2024.

Vera Therapeutics CEO, Marshall Fordyce, engaged in multiple transactions involving the acquisition and sale of company stock, including the exercise of stock options, under a pre-arranged 10b5-1 trading plan.